Proellex: Phase II start

Repros said FDA converted a full clinical hold on additional trials of oral Proellex to a partial hold to allow the company to conduct a placebo-controlled Phase II trial evaluating low-dose Proellex. The company believes data from the Phase II trial, which will evaluate 6 and 12 mg Proellex for 4 months in 90 patients, will allow the partial hold to be lifted. The trial is slated to begin this quarter. ...